ASRT Earnings Prediction
The chart below shows how ASRT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ASRT sees a -3.69% change in stock price 10 days leading up to the earnings, and a -7.54% change 10 days following the report. On the earnings day itself, the stock moves by +2.99%. This data can give you a slight idea of what to expect for the next quarter's release.
ASRT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
32.18M
-2.43%
10.20%
Gross Margin
43.19%
-22.94%
-15.81%
Operating Margin
-27.35%
38.97%
190.65%
Net Margin
-32.55%
-81.29%
225.50%
EPS
-0.11
-81.67%
266.67%
No Data Available
ASRT Earnings Analysis
Assertio Holdings Inc Corporation (ASRT.O) Earnings Conference Call
Positive
Rolvedon Sales Success: Assertio exceeded $60 million in Rolvedon sales, demonstrating strong performance in the community oncology clinic segment.
Operating Cash Flow Achievement: The company generated $26.4 million in operating cash flows in 2024, exceeding the high-end cash goal of $100 million.
Strong Sales Performance: Rolvedon sales exceeded expectations at $60.1 million for the full year, indicating strong market acceptance and demand.
Indocin Sales Performance: Indocin sales also exceeded expectations at $26.8 million, showcasing resilience despite generic competition.
Commercial Pilot Project Success: The company completed a commercial pilot project for Sympazan, confirming that growth is probable with in-person promotion.
Leadership Appointments and Strategy: Assertio made significant leadership appointments, including Mary Pietryga as Chief Commercial Officer and Paul Schwichtenberg as Chief Transformation Officer, enhancing its strategic direction.
Balance Sheet Strengthening: The company strengthened its balance sheet, positioning itself for future growth and strategic opportunities.
Negative
Earnings Miss Report: Assertio Holdings, Inc. missed earnings expectations with a reported EPS of $-0.11, compared to expectations of $-0.05.
Net Income Loss Increase: The company reported a GAAP net income loss of $10.5 million in Q4, which is a significant increase from a loss of $2.9 million in Q3.
Q4 Adjusted EBITDA Loss: Adjusted EBITDA for Q4 was a loss of $0.5 million, down from income of $5.3 million in the prior quarter, impacted by inventory write-downs and litigation contingencies.
Gross Margin Decline: Gross margin decreased to 61% in Q4 from 74% in Q3, primarily due to a $2.9 million write-down of excess inventory for Indocin, which faced generic competition.
Increased Operating Expenses: Total adjusted operating expenses for the year were $73.7 million, higher than expectations, mainly due to increased litigation-related costs.
Inventory Write-Down Impact: The company faced a $4.2 million write-down for Indocin excess inventory, which negatively impacted gross margins and overall financial performance.
Sales Growth Challenges: Rolvedon sales, while exceeding expectations at $60.1 million, are expected to face challenges in growth due to the competitive long-acting G-CSF market and the decline of Indocin.
2025 Financial Outlook Uncertainty: The outlook for 2025 includes uncertainty, with guidance for net sales between $108 million and $123 million, and adjusted EBITDA of $10 million to $19 million, indicating potential struggles ahead.
ASRT FAQs
How does ASRT typically perform around its earnings report dates?
Is Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ASRT Earning Call Sentiment
Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2024 Earnings Call Transcript
ASRT.O
-2.05%Positive
The earnings call highlights several negative factors: increased litigation costs, competitive market risks, and uncertain sales guidance. While Rolvedon sales exceeded expectations, the gross margin decline and higher operational expenses, driven by litigation contingencies, weigh heavily. The Q&A session reveals uncertainties in market expansion and legal exposures. Despite the potential for acquisitions, the lack of a share repurchase program and the significant financial challenges suggest a negative outlook for the stock price over the next two weeks.
